Drug Profile
Panitumumab companion diagnostic - Amgen/Biocartis
Alternative Names: IdyllaTM KRAS mutation test; IdyllaTM NRAS-BRAF mutation testLatest Information Update: 28 Nov 2021
Price :
$50
*
At a glance
- Originator Biocartis
- Developer Amgen; Biocartis
- Class Diagnostic agents
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Colorectal cancer
Most Recent Events
- 28 Nov 2021 No recent reports of development identified for clinical-Phase-Unknown development in Colorectal-cancer(Diagnosis, Metastatic disease) in USA
- 19 Oct 2018 Clinical trials in Colorectal cancer (Diagnosis, Metastatic disease) in USA (unspecified route) before October 2018
- 04 Dec 2017 Biocartis entered into an agreement with Amgen to develop Idylla™ RAS biomarker tests for Colorectal cancer